Abstract Number: 1559 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Medication Use Among Arab Patients with Rheumatoid Arthritis in Some Arab States
Background/Purpose: Data on the clinical and genetic characteristics of Arab patients with Rheumatoid Arthritis (RA) is limited. Our aim is to report on the clinical…Abstract Number: 1560 • 2015 ACR/ARHP Annual Meeting
The Effect of Anti Estrogen Therapy (AET) on Rheumatoid Arthritis
Background/Purpose: The well-known positive effect of pregnancy on improving Rheumatoid Arthritis (RA) disease activity suggests that hormonal changes may play a role in disease pathogenesis…Abstract Number: 1561 • 2015 ACR/ARHP Annual Meeting
The Effect of TNF Blockers on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
Background/Purpose: Osteoporosis is more frequently observed in patients with rheumatoid arthritis (RA) than in general population. Bisphosphonate (BP), which suppresses bone resorption by inhibiting osteoclast…Abstract Number: 1562 • 2015 ACR/ARHP Annual Meeting
Clinical Correlates, Outcomes and Predictors of Episcleritis and Scleritis Associated with Rheumatoid Arthritis
Background/Purpose: Inflammatory ocular disease (IOD) has traditionally been regarded as a severe extra-articular manifestation of rheumatoid arthritis (RA) with high mortality. This study aims to…Abstract Number: 1563 • 2015 ACR/ARHP Annual Meeting
Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort
Background/Purpose: Previous studies showed that obesity in patients with rheumatoid arthritis (RA) is associated with higher disease activity. Beyond obesity, cardiometabolic disturbances may impact the…Abstract Number: 1564 • 2015 ACR/ARHP Annual Meeting
Initiation of Disease Modifying Therapies and Subsequent Weight Change in Rheumatoid Arthritis
Background/Purpose: Low body mass index (BMI) predicts adverse outcomes in rheumatoid arthritis (RA), in part due to weight loss among patients with severe disease and…Abstract Number: 1565 • 2015 ACR/ARHP Annual Meeting
High Disease Activity over Time and Persistent Inflammation Are Associated with Increased Risk of Cardiovascular Disease in Patients with Early Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased rate of cardiovascular (CV) disease. Systemic inflammation has been implicated as a key factor behind CV…Abstract Number: 1566 • 2015 ACR/ARHP Annual Meeting
The Impact of Severe Extra-Articular Manifestations and Patient Reported Outcome Measures on Cardiovascular Disease in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD). Disease severity, including extra-articular rheumatoid arthritis (ExRA) manifestations, has previously been demonstrated…Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…Abstract Number: 1568 • 2015 ACR/ARHP Annual Meeting
Cardiac Morphology and Function in Patients with Acute Coronary Syndrome Complicated with Rheumatoid Arthritis
Background/Purpose: Cardiovascular diseases are important contributors to the excess of overall morbidity and mortality in patients with rheumatoid arthritis (RA). The aim of this study…Abstract Number: 1569 • 2015 ACR/ARHP Annual Meeting
Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis
Background/Purpose: To investigate the efficacy and safety of rituximab (RTX) in the the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: An…Abstract Number: 1570 • 2015 ACR/ARHP Annual Meeting
End Stage Renal Disease (ESRD) in Patients with Rheumatoid Arthritis
Background/Purpose: Substantial progress has been made in the treatment of rheumatoid arthritis (RA) and life expectancy has increased. As the population of patients with RA…Abstract Number: 1571 • 2015 ACR/ARHP Annual Meeting
How Substantive Is Heart Rate Variability As a Predictor of Anti-TNF Treatment Outcome for Inflammatory Arthritis?
Background/Purpose: As rheumatologists search for new targets to improve immunosuppressive outcomes, the autonomic nervous system (ANS) as a co-factor in autoimmune disease expression has gained…Abstract Number: 1572 • 2015 ACR/ARHP Annual Meeting
Plasma Apolipoprotein B48 Levels in Patients with Rheumatoid Arthritis: Evaluating Novel Cardiovascular Risk Factors
Background/Purpose: Chylomicrons, with apolipoprotein (apo) B48 as a structural protein, induce leukocyte and complement activation and contribute to atherosclerosis. ApoB48 is higher in conditions associated…Abstract Number: 1573 • 2015 ACR/ARHP Annual Meeting
Plasma Pentraxin 3 Concentration Is Associated with Progression of Radiographic Joint Damage but Not with Carotid Atherosclerosis in Female Patients with Rheumatoid Arthritis: Results from a 3-Year Prospective Study
Background/Purpose: Pentraxin 3 (PTX3) plays an important role in inflammation, immunity, and atherosclerosis. Plasma PTX3 level is recognized as a marker that responds to local…